Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Biosimilars: European Payer Perspectives (2017)

Product Code:
SUL-7FD55D6F
Publication Date:
January 2017
Format:
PDF
Price:
$2,245

What is the future for biosimilars in the EU?

What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars?

In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of Enbrel marking a significant advance in biosimilar therapy options.  With biosimilar versions of Avastin and Herceptin in the pipeline, the sector is on the verge of delivering lower cost yet equally effective medicines.  Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. As the market matures, expect wider clinical adoption and patient support, though questions around price discounting and substitution remain unresolved.  

You're just a couple of clicks away from finding out Payers candid views of biosimilars. This report is available for immediate download after purchase -- buy your report now.

Report Overview

For a complete understanding turn to Biosimilars: European Payer Perspectives 2017, a report that reveals the latest insights of EU payers and the issues they see as being critical for the sector’s development. Buy the report now.

Report Features

  • In-depth interviews reveal unique and frank insights from 15 national and regional payers in Germany, France, Italy, Spain and the UK
  • Table summarising existing biosimilar approvals and current regulatory pipeline to the EMA
  • At-a-glance summaries of all the key insights

Key Benefits

  • Understand how the biosimilar market has grown in 2016 and what are the stand out developments
  • Investigate national trends driving adoption, pricing and reimbursement of biosimilars. 
  • Examine how biosimilar cost savings are being reinvested in health and the positive impact this is having on payer perceptions
  • Gain insight into the role of patient groups whose voice is becoming increasingly heard in biosimilars discussions
  • Assess the current climate for price discounting and why a uniform price reduction is unlikely among EU member states 
  • Review the ongoing arguments for switching from originator to biosimilar products and learn how they differ at the national level
  • Create communication strategies that challenge misinformation and instil confidence in clinicians and patients

Report available for immediate download -- place your order today

Key Questions Answered By This Report

  • Market movements: What biosimilar products were approved in 2016 and which companies have been most active?  
  • Discounts: 25%, 50% 70% – payers want significant discounts for biosimilars, but what is the right level and should it be available to everyone? 
  • Switching: What are the national obstacles to switching from a brand to a biosimilar, and is there a role for developers in bringing about change? 
  • Fear factor: Clinician and patient fear is limiting biosimilar adoption. Education can help, but who should be responsible for its creation and can industry have a role?
  • Misinformation: What can biosimilar developers do to defend their products from originator misinformation about the safety and efficacy of biosimilar products? 
  • Italian job: What market and regulatory developments make Italy a biosimilar market to watch for biosimilar companies?

Report available for immediate download -- place your order now

Expert Views

To ensure candid views were expressed, the names of payers have been kept anonymous.  Each contributor has been carefully selected for their experience and detailed knowledge of the national and regional biosimilar market and their insights provide a unique front line perspective for industry.
United Kingdom Payers:
  • Herefordshire CCG
  • West Hampshire CCG
  • Wokingham CCG
French Payers:
  • AP-HP Villejuif
  • CHU Grenoble
  • CHU AP-HP Garches
German Payers:
  • G-BA/Physicians Association
  • Statutory Health Insurance (SHI)
  • G-BA/Physicians Association

Spanish Payers:

  • Regional Payer: Valencia
  • Regional Payer: Basque County
  • Regional Payer: Cataluna

Italian Payers:

  • National Payer: Piedmont
  • Regional Payer: Sicily
  • Regional Payer: Emilia-Romagna

4 Key Quotes

“Obviously biosimilars are giving us significant cost savings because they are cheaper than the originator molecules with all the same indications. So certainly in my area, we are very pro biosimilars. But for us locally, the reason that we’ve been able to switch [to biosimilars] is because we’ve shared savings with secondary care commissions. It’s allowed us to develop the service and the feedback from patients is actually that it’s better than it was before because they’ve got more time, they are being monitored more closely and they just feel there are getting more out of the service than they were when they were on a branded product, indirectly, because we have invested the money back into the service.”
UK Payer

“It is my personal thinking that it would be better to have the possibility to distinguish [between originator biologics and biosimilars]. I do not understand why having another non-proprietary name is a problem. We have this already with several substances. So of course, it’s not really a problem and they can do this in my opinion. It will improve the safety.”
German Payer

“Formulary inclusion has been quite quick, once the product has been authorised. In fact, I think it has accelerated a bit and it will be accelerated in the future too because the market is growing. So at the regulatory level, AIFA and EMA, they have accepted this market, which they looked at with misgivings before. The process has accelerated, because all the verification processes are streamlined.”
Italian Payer

 

“At this time it should be [the choice of physicians]. We need perhaps one or two more years to ensure that we don’t have a problem with safety, that we don’t have a problem in immunogenicity, for example. But after that, I think the pharmacists should be aware and should be able to switch like the generics.” 

French Payer

Critical insights from these and many other respected experts available for immediate download —place your order here

 

Who Would Benefit from This Report?

  • Commercial teams negotiating biosimilar prices and discounts with payers
  • Marketing teams communicating the benefits and safety of biosimilars
  • Medical affairs teams building the evidence case for biosimilars with physicians and payers
  • MSL teams engaging with physicians about biosimilar safety and efficacy
  • Market research and HEOR teams analysing long-term real world data on biosimilar use and outcomes

Report available for immediate download — place your order now

Content Highlights

  • Executive summary
  • Biosimilars in Europe: Where we currently stand
    • Biosimilar approvals in Europe to date
    • Uptake and usage of biosimilars in Europe
    • Awareness and perceptions of biosimilars
    • New biosimilar approvals, increased regulatory clarity, push for cost savings top changes over past 12 months
    • Promoting cost-savings remains most prominent way for countries to boost biosimilar use
    • Physicians remain key driver in biosimilar adoption; patient groups growing increasingly vocal
    • Complexity of biosimilars remains key barrier to uptake; manufacturer information  also an issue
    • KOLs remain unsure who should head up biosimilar education efforts
    • Approval of Benepali viewed as turning point for biosimilar awareness
  • Regulations:
    • KOLs supportive of current regulatory oversight, but need greater guidance on switching
    • Regulations satisfactory for formulary decisions, particularly in indication extrapolation
    • Increased insight into manufacturing process, real world data could bolster confidence in market
    • Recent regulatory changes to further define biosimilars welcomed by KOLs
    • EC orphan drug legislation isn’t expected to have significant impact
  • Biosimilar approval, use and tracking:
    • Current naming policies falling short of KOL expectations
    • Non-inferiority should be sufficient grounds for regulatory approval, except for indication extrapolation
    • Acceptance of indication extrapolation continues, but is siloed by specialty
    • KOLs remain generally positive about interchangeability
    • Switching permissible in treatment naïve patients; existing patients represent a new growth area 
    • Pharmacy-level substitution remains a hot button issue, but option may be on the horizon
    • Education key to switching support, but KOLs unsure of who should provide data
    • Physician fears, market turbulence and originator company misinformation remain barriers
    • EMA has significant role to play in biosimilar adoption, but may not be best for general oversight
    • Physicians should have final say on interchangeability for now, but times could be changing
  • Commercialisation issues:
    • Cost savings remain primary driver of biosimilar appeal
    • Fuelled by progress in Scandanavian countries, KOLs push for deeper discounts
    • Discounts in select EU markets could become replicable in near future
    • Scandanavian countries leading the way in biosimilar uptake, but select EU states gaining ground
    • Price-matching biosimilars to originator therapies remains unlikely
  • Future challenges/opportunities for biosimilars in Europe
    • Lack of guidance on switching remains primary barrier to greater biosimilar adoption
    • Potential for cost savings remains greatest opportunity for biosimilars
    • EU no closer to accepting biosimilars as ‘generic’ versions of reference products
    • Physicians remain most influential on future acceptance, but other stakeholders cannot be ignored
    • Opportunity to learn from US limited, as market dynamics too dissimilar to EU

This critical intelligence is available for immediate download — order your copy now

Need more information? Contact a consultant for an executive summary and sample pages from the report.

Get this report now

What is the future for biosimilars in the EU?

What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars?

In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of Enbrel marking a significant advance in biosimilar therapy options.  With biosimilar versions of Avastin and Herceptin in the pipeline, the sector is on the verge of delivering lower cost yet equally effective medicines.  Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. As the market matures, expect wider clinical adoption and patient support, though questions around price discounting and substitution remain unresolved.  

You're just a couple of clicks away from finding out Payers candid views of biosimilars. This report is available for immediate download after purchase -- buy your report now.

Report Overview

For a complete understanding turn to Biosimilars: European Payer Perspectives 2017, a report that reveals the latest insights of EU payers and the issues they see as being critical for the sector’s development. Buy the report now.

Report Features

  • In-depth interviews reveal unique and frank insights from 15 national and regional payers in Germany, France, Italy, Spain and the UK
  • Table summarising existing biosimilar approvals and current regulatory pipeline to the EMA
  • At-a-glance summaries of all the key insights

Key Benefits

  • Understand how the biosimilar market has grown in 2016 and what are the stand out developments
  • Investigate national trends driving adoption, pricing and reimbursement of biosimilars. 
  • Examine how biosimilar cost savings are being reinvested in health and the positive impact this is having on payer perceptions
  • Gain insight into the role of patient groups whose voice is becoming increasingly heard in biosimilars discussions
  • Assess the current climate for price discounting and why a uniform price reduction is unlikely among EU member states 
  • Review the ongoing arguments for switching from originator to biosimilar products and learn how they differ at the national level
  • Create communication strategies that challenge misinformation and instil confidence in clinicians and patients

Report available for immediate download -- place your order now

Key Questions Answered By This Report

  • Market movements: What biosimilar products were approved in 2016 and which companies have been most active?  
  • Discounts: 25%, 50% 70% – payers want significant discounts for biosimilars, but what is the right level and should it be available to everyone? 
  • Switching: What are the national obstacles to switching from a brand to a biosimilar, and is there a role for developers in bringing about change? 
  • Fear factor: Clinician and patient fear is limiting biosimilar adoption. Education can help, but who should be responsible for its creation and can industry have a role?
  • Misinformation: What can biosimilar developers do to defend their products from originator misinformation about the safety and efficacy of biosimilar products? 
  • Italian job: What market and regulatory developments make Italy a biosimilar market to watch for biosimilar companies?

Report available for immediate download -- place your order today

Expert Views

To ensure candid views were expressed, the names of payers have been kept anonymous.  Each contributor has been carefully selected for their experience and detailed knowledge of the national and regional biosimilar market and their insights provide a unique front line perspective for industry.
United Kingdom Payers:
  • Herefordshire CCG
  • West Hampshire CCG
  • Wokingham CCG
French Payers:
  • AP-HP Villejuif
  • CHU Grenoble
  • CHU AP-HP Garches
German Payers:
  • G-BA/Physicians Association
  • Statutory Health Insurance (SHI)
  • G-BA/Physicians Association

Spanish Payers:

  • Regional Payer: Valencia
  • Regional Payer: Basque County
  • Regional Payer: Cataluna

Italian Payers:

  • National Payer: Piedmont
  • Regional Payer: Sicily
  • Regional Payer: Emilia-Romagna

4 Key Quotes

“Obviously biosimilars are giving us significant cost savings because they are cheaper than the originator molecules with all the same indications. So certainly in my area, we are very pro biosimilars. But for us locally, the reason that we’ve been able to switch [to biosimilars] is because we’ve shared savings with secondary care commissions. It’s allowed us to develop the service and the feedback from patients is actually that it’s better than it was before because they’ve got more time, they are being monitored more closely and they just feel there are getting more out of the service than they were when they were on a branded product, indirectly, because we have invested the money back into the service.”
UK Payer

“It is my personal thinking that it would be better to have the possibility to distinguish [between originator biologics and biosimilars]. I do not understand why having another non-proprietary name is a problem. We have this already with several substances. So of course, it’s not really a problem and they can do this in my opinion. It will improve the safety.”
German Payer

“Formulary inclusion has been quite quick, once the product has been authorised. In fact, I think it has accelerated a bit and it will be accelerated in the future too because the market is growing. So at the regulatory level, AIFA and EMA, they have accepted this market, which they looked at with misgivings before. The process has accelerated, because all the verification processes are streamlined.”
Italian Payer

 

“At this time it should be [the choice of physicians]. We need perhaps one or two more years to ensure that we don’t have a problem with safety, that we don’t have a problem in immunogenicity, for example. But after that, I think the pharmacists should be aware and should be able to switch like the generics.” 

French Payer

Critical insights from these and many other respected experts available for immediate download —place your order now

 

Who Would Benefit from This Report?

  • Commercial teams negotiating biosimilar prices and discounts with payers
  • Marketing teams communicating the benefits and safety of biosimilars
  • Medical affairs teams building the evidence case for biosimilars with physicians and payers
  • MSL teams engaging with physicians about biosimilar safety and efficacy
  • Market research and HEOR teams analysing long-term real world data on biosimilar use and outcomes

Report available for immediate download — place your order here

Content Highlights

  • Executive summary
  • Biosimilars in Europe: Where we currently stand
    • Biosimilar approvals in Europe to date
    • Uptake and usage of biosimilars in Europe
    • Awareness and perceptions of biosimilars
    • New biosimilar approvals, increased regulatory clarity, push for cost savings top changes over past 12 months
    • Promoting cost-savings remains most prominent way for countries to boost biosimilar use
    • Physicians remain key driver in biosimilar adoption; patient groups growing increasingly vocal
    • Complexity of biosimilars remains key barrier to uptake; manufacturer information  also an issue
    • KOLs remain unsure who should head up biosimilar education efforts
    • Approval of Benepali viewed as turning point for biosimilar awareness
  • Regulations:
    • KOLs supportive of current regulatory oversight, but need greater guidance on switching
    • Regulations satisfactory for formulary decisions, particularly in indication extrapolation
    • Increased insight into manufacturing process, real world data could bolster confidence in market
    • Recent regulatory changes to further define biosimilars welcomed by KOLs
    • EC orphan drug legislation isn’t expected to have significant impact
  • Biosimilar approval, use and tracking:
    • Current naming policies falling short of KOL expectations
    • Non-inferiority should be sufficient grounds for regulatory approval, except for indication extrapolation
    • Acceptance of indication extrapolation continues, but is siloed by specialty
    • KOLs remain generally positive about interchangeability
    • Switching permissible in treatment naïve patients; existing patients represent a new growth area 
    • Pharmacy-level substitution remains a hot button issue, but option may be on the horizon
    • Education key to switching support, but KOLs unsure of who should provide data
    • Physician fears, market turbulence and originator company misinformation remain barriers
    • EMA has significant role to play in biosimilar adoption, but may not be best for general oversight
    • Physicians should have final say on interchangeability for now, but times could be changing
  • Commercialisation issues:
    • Cost savings remain primary driver of biosimilar appeal
    • Fuelled by progress in Scandanavian countries, KOLs push for deeper discounts
    • Discounts in select EU markets could become replicable in near future
    • Scandanavian countries leading the way in biosimilar uptake, but select EU states gaining ground
    • Price-matching biosimilars to originator therapies remains unlikely
  • Future challenges/opportunities for biosimilars in Europe
    • Lack of guidance on switching remains primary barrier to greater biosimilar adoption
    • Potential for cost savings remains greatest opportunity for biosimilars
    • EU no closer to accepting biosimilars as ‘generic’ versions of reference products
    • Physicians remain most influential on future acceptance, but other stakeholders cannot be ignored
    • Opportunity to learn from US limited, as market dynamics too dissimilar to EU

This critical intelligence is available for immediate download —order your copy here

Need more information? Contact a consultant for an executive summary and sample pages from the report.

Get this report now




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved